Table 2.
PGL cohorts stratified by the PASS algorithm.
| Study No. | First Author | Year Published | Number of PGLs * | Number of Malignant PGLs * | Definition of Malignant PGLs | Mal PGLs PASS ≥ 4 | Mal PGLs PASS < 4 | Benign PGLs PASS ≥ 4 | Benign PGLs PASS < 4 | SENS | SPEC | PPV | NPV |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | August | 2004 | 6 | 6 | MET | 6 | 0 | 0 | 0 | 100% | - | 100% | - |
| 2 | Szalat | 2010 | 1 | 1 | MET | 1 | 0 | 0 | 0 | 100% | - | 100% | - |
| 3 | Kulkarni | 2016 | 4 | 2 | MET | 2 | 0 | 0 | 2 | 100% | 100% | 100% | 100% |
| 4 | Kim | 2016 | 29 | 16 | REC/MET | npd | 0 | npd | 15 | npd | npd | npd | npd |
| 5 | Koh | 2017 | 5 | 0 | MET | 0 | 0 | 3 | 2 | npd | npd | npd | npd |
| 6 | Stenman | 2018 | 11 | 4 | REC/MET | 4 | 0 | 5 | 2 | 100% | 29% | 44% | 100% |
| Summarized | - | 56 | 29 | - | 13 | 0 | 8 | 21 | 100% | 72% | 62% | 100% | |
PGL—paraganglioma, MET—metastatic disease, REC—recurrence, ns—not specified, npd—not possible to determine, SENS -sensitivity, SPEC—specificity; ns -not specified, npd—not possible to determine, PPV—positive predictive value, NPV—negative predicitive value; *—Numbers correspond to cases histologically investigated, which is not necessarily identical to cases included in the study as a whole. Numbers in bold script at the bottom represent summarized values for all parameters, with corresponding SENS, SPEC, PPV and NPV values calculated for these sums.